Citi Downgrades Puma Biotechnology (PBYI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Price: $10.90 +1.30%
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
5 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Neutral with a price target of $24.00.
For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.
Shares of Puma Biotechnology closed at $19.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX (SPCX) added to Citi 90-day upside catalyst watch list
- Needham Downgrades Netflix (NFLX) to Hold
- Citi Downgrades PT Telekomunikasi Indonesia Tbk (TLKM:IJ) (TLKMF) to Neutral
Create E-mail Alert Related Categories
DowngradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
